Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 4

Sponsor Class

INDUSTRY 196OTHER 174NIH 11NETWORK 9UNKNOWN 4OTHER_GOV 4

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Hormone Receptor Positive Advanced Breast Cancer 1

Interventions

Paclitaxel 7Epirubicin 7Capecitabine 7pyrotinib 5Docetaxel 5Carboplatin 5Vinorelbine 4Fulvestrant 4Cyclophosphamide 4exemestane 3anlotinib 3Radiotherapy 3Radiation Dose Hypofractionation 3Etoposide 3pirarubicin 2palbociclib 2apatinib 2Standard of Care 2Neoadjuvant Therapy 2Letrozole 2Albumin-Bound Paclitaxel 2toripalimab 1titanium silicide 1nimotuzumab 1neratinib 1lobaplatin 1liposomal doxorubicin 1icaritin 1eribulin 1Zoledronic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
UNKNOWN × Fulvestrant × Breast × Clear all
NCT05000736 2022-04-29

CAPACITY

ChineseAMS

Unknown
600 enrolled
Breast

Hormone Receptor Positive Advanced Breast Cancer

NCT04289974 2020-02-28

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

ChineseAMS

Unknown
100 enrolled
Breast

Breast Neoplasms

NCT04033172 2019-07-25

Pyrotinib

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT02646735 2017-01-02

FRIEND

ChineseAMS

Phase 2 Unknown
148 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡